menu
    • menu
    [{"orgOrder":0,"company":"Tianjin Tiancheng Pharma. Co., Ltd.","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$1,281.5 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patients\u2019 Access to Plasma Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"BT524","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tianjin Tiancheng Pharma. Co., Ltd.","amount2":1.28,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.28,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols"}]

    Find Clinical Drug Pipeline Developments & Deals by Tianjin Tiancheng Pharma. Co., Ltd.

    Menu

    Tianjin Tiancheng Pharma. Co., Ltd.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    Ă—
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tianjin Tiancheng Pharma. Co., Ltd.

                            China arrow
                            Discovery on Target
                            Not Confirmed

                            Tianjin Tiancheng Pharma. Co., Ltd.

                            China arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BT524

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Grifols International

                            Deal Size : $1,281.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patientsâ€...

                            Details : This acquisition will significantly reinforce Grifols’ industry capabilities by enhancing its plasmaderived medicines access, pipeline Biotest is leading clinical trials on plasma-derived fibrinogen (BT524) to treat congenital and acquired disorders.

                            Brand Name : BT524

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 17, 2021

                            Lead Product(s) : BT524

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Grifols International

                            Deal Size : $1,281.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth